BRAF mutations, particularly at codon 600, are found in almost 50% of the cutaneous melanomas [37], which has led to the successful treatment using BRAF-selective inhibitors, vemurafenib, and dabrafenib, resulting in a prolongation of progression-free and overall survival. The gene discussed is BRAF; the disease is cutaneous melanoma.